Latest news

Daily Snap - 4. September 2025

Daily Snap - 4. September 2025

Joachim Eeckhout
FDA proposes rare disease drug pathway but analysts question its real impact

FDA proposes rare disease drug pathway but analysts question its real impact

Eduardo Longoria
Novartis doubles down on RNAi heart drugs with $160M Argo deal

Novartis doubles down on RNAi heart drugs with $160M Argo deal

Eduardo Longoria
Daily Snap - 3. September 2025

Daily Snap - 3. September 2025

Joachim Eeckhout
Novartis bets $2.2B on Arrowhead’s RNA brain drug to crack Parkinson’s code

Novartis bets $2.2B on Arrowhead’s RNA brain drug to crack Parkinson’s code

Eduardo Longoria
Editas pivots to tackle high cholesterol with gene editing breakthrough

Editas pivots to tackle high cholesterol with gene editing breakthrough

Eduardo Longoria
Daily Snap - 2. September 2025

Daily Snap - 2. September 2025

Joachim Eeckhout
Wegovy cuts heart risk by 57% over Zepbound in real-world study

Wegovy cuts heart risk by 57% over Zepbound in real-world study

Joachim Eeckhout
Daily Snap - 1. September 2025

Daily Snap - 1. September 2025

Joachim Eeckhout
FDA clears at-home Leqembi injection, transforming Alzheimer’s maintenance care

FDA clears at-home Leqembi injection, transforming Alzheimer’s maintenance care

Eduardo Longoria
Sanofi’s Wayrilz becomes first FDA-approved BTK drug for a rare bleeding disorder

Sanofi’s Wayrilz becomes first FDA-approved BTK drug for a rare bleeding disorder

Eduardo Longoria
Novo Nordisk bets $550M on RNA tech to revive obesity, diabetes drug pipeline

Novo Nordisk bets $550M on RNA tech to revive obesity, diabetes drug pipeline

Eduardo Longoria
FirstBack
12345678
Next Last